1/9
08:02 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
1/8
07:27 am
enta
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook [Yahoo! Finance]
1/8
07:00 am
enta
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
Low
Report
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
1/5
07:13 am
enta
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
07:00 am
enta
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/1
08:35 am
enta
Enanta Pharmaceuticals Insider Ups Holding During Year [Yahoo! Finance]
Medium
Report
Enanta Pharmaceuticals Insider Ups Holding During Year [Yahoo! Finance]
11/19
03:03 pm
enta
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development [Seeking Alpha]
Low
Report
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development [Seeking Alpha]
11/17
04:45 pm
enta
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 [Yahoo! Finance]
11/17
04:12 pm
enta
Enanta Pharma GAAP EPS of -$0.87, revenue of $15.1M [Seeking Alpha]
Medium
Report
Enanta Pharma GAAP EPS of -$0.87, revenue of $15.1M [Seeking Alpha]
11/17
04:01 pm
enta
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
Low
Report
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
11/14
08:09 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $17.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $17.00 price target on the stock.
11/4
07:00 am
enta
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
10/24
12:22 pm
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.